Comparable stake leader
Fairmount Funds Management LLC
SEC ownership of Oruka Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000907654.
Disclosed value leader
Fairmount Funds Management LLC
Comparable rows
50/50
Latest evidence
01 Jul 2026
- Public ticker
- ORKA on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Fairmount Funds Management LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Fairmount Funds Management LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
01 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000907654
- Issuer location
- Menlo Park, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Oruka Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Fairmount Funds Managemen...
Disclosed value leader
Fairmount Funds Managemen...
Comparable rows
50/50
Latest evidence
01 Jul 2026
13D/G
3/4/5
13F
Lead comparable stake: 20%
13D/G row: Fairmount Funds Management LLC
Showing 1-8 of 50 holder rows.
Quick read
Fairmount Funds Management LLC leads the comparable SEC ownership view at 20%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Fairmount Funds Management LLC's linked filing trail.
Comparable ownership
Top 5
Fairmount Funds Management LLC
20%
Venrock Healthcare Capital Partne...
7.4%
BlackRock, Inc.
6.6%
Capital World Investors
5.6%
RTW INVESTMENTS, LP
5.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC |
13D/G
3/4/5
13F
Harwin Peter Evan · Director, 10%+ Owner · Company
|
20%
|
$997,807,627
14,572,917 shares
|
+$62,159,599 | 01 Jul 2026 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
3/4/5
10%+ Owner
|
7.4%
|
$384,606,749
4,556,952 shares
|
-$29,765,095 | 30 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
6.6%
from 13D/G
|
$474,915,526
4,990,181 shares
|
— | 30 Jun 2026 |
| Capital World Investors |
13F
13D/G
Company
|
5.6%
from 13D/G
|
$323,733,984
3,401,639 shares
|
— | 30 Jun 2026 |
| RTW INVESTMENTS, LP |
13F
13D/G
Company
|
5.2%
from 13D/G
|
$298,741,485
3,139,030 shares
|
— | 30 Jun 2026 |
| Deep Track Capital, LP |
13F
13D/G
Company
|
4.5%
from 13D/G
|
$183,297,420
1,926,000 shares
|
— | 30 Jun 2026 |
| VIKING GLOBAL INVESTORS LP |
13F
13D/G
Company
|
2.5%
from 13D/G
|
$143,086,001
1,503,478 shares
|
— | 30 Jun 2026 |
| FMR LLC |
13F
Company
|
15%
|
$862,016,075
9,057,645 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$1,530,537,388.
Buys
$0
Insiders: 0
Sells
$1,530,537,388
Insiders: 11
Net
-$1,530,537,388
Shares: -18,179,887
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 18,179,887
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 17,951,040 | $0 | $1,517,751,670 | -$1,517,751,670 |
| 3-6 | 0 | 189,847 | $0 | $11,583,545 | -$11,583,545 |
| 6-9 | 0 | 39,000 | $0 | $1,202,173 | -$1,202,173 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 31 reporting-owner rows connected to Oruka Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
31
Largest Forms 3/4/5 holder
Fairmount Healthcare Fund II L.P.
Net 12M change
-$1,530,537,387
Latest report
01 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Fairmount Healthcare Fund II L.P. | Director, 10%+ Owner | $221,791,633 | -$300,014,406 | -57% | Mixed | 01 Jul 2026 |
| Fairmount Funds Management LLC | Director, 10%+ Owner | $221,791,633 | -$300,014,406 | -57% | Mixed | 01 Jul 2026 |
| Tomas Kiselak | Director, 10%+ Owner | $221,791,633 | -$300,014,406 | -57% | Mixed | 01 Jul 2026 |
| Fairmount Healthcare Co-Invest III L.P. | Director, 10%+ Owner | $221,791,633 | -$300,014,406 | -57% | Mixed | 01 Jul 2026 |
| Peter Evan Harwin | Director, 10%+ Owner | $221,791,633 | -$300,014,406 | -57% | Mixed | 01 Jul 2026 |
| Lawrence Otto Klein | Chief Executive Officer, Director | $85,556,635 | -$7,079,386 | -7.6% | Filing P/S | 01 Sep 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 10%+ Owner | $47,458,016 | Filing P/S | 10 Feb 2025 | ||
| Funicular Funds, LP | Other*, 10%+ Owner | $22,903,390 | Mixed | 15 Dec 2022 | ||
| Laura Lee Sandler | Chief Operating Officer | $21,750,495 | -$1,855,775 | -7.9% | Filing P/S | 01 Sep 2026 |
| Larry Todd Edwards | Chief Commercial Officer | $9,517,000 | Median | 24 Aug 2026 | ||
| Funicular Fund, LP | Other* | $6,451,130 | Mixed | 23 May 2022 | ||
| Janus Henderson Group Ltd. | 10%+ Owner | $6,302,520 | Filing P/S | 16 Aug 2024 | ||
| Joana Goncalves | Chief Medical Officer | $3,682,810 | -$3,809,307 | -51% | Filing P/S | 17 Aug 2026 |
| Quinlan Paul T. | General Counsel | $3,449,050 | -$5,722,765 | -62% | Filing P/S | 14 Aug 2026 |
| Carl Dambkowski | Director | $2,716,232 | -$8,645,748 | -76% | Filing P/S | 11 Jun 2026 |
| Arjun Agarwal | Senior Vice President, Finance | $1,660,782 | -$3,352,376 | -67% | Filing P/S | 13 Aug 2026 |
| Cameron Turtle | Director | $253,722 | Mixed | 02 Jun 2025 | ||
| Christopher David Ozeroff | S.V.P., General Counsel | $127,425 | Mixed | 14 Dec 2021 | ||
| Robert E. Conway | Director, Chairman of the Board | $125,000 | Mixed | 30 Jan 2024 | ||
| Thomas A. Keuer | Chief Operating Officer | $101,825 | Mixed | 08 Dec 2022 |
Recent insider transactions for Oruka Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Laura Lee Sandler | ORKA | Common Stock | Sale | -2.07% | $459,101 | $91.82 | -5,000 | 236,384 | 01 Sep 2026 | Direct |
| Laura Lee Sandler | ORKA | Common Stock | Options Exercise | 2.12% | 5,000 | 241,384 | 01 Sep 2026 | Direct | ||
| Laura Lee Sandler | ORKA | Employee Warrant (right to buy) | Options Exercise | -6.25% | -5,000 | 74,996 | 01 Sep 2026 | Direct | ||
| Lawrence Otto Klein | ORKA | Common Stock | Sale | -7.5% | $6,887,484 | $91.83 | -75,000 | 925,580 | 01 Sep 2026 | Direct |
| Lawrence Otto Klein | ORKA | Common Stock | Options Exercise | 8.1% | 75,000 | 1,000,580 | 01 Sep 2026 | Direct | ||
| Lawrence Otto Klein | ORKA | Employee Warrant (right to buy) | Options Exercise | -4.61% | -75,000 | 1,553,513 | 01 Sep 2026 | Direct | ||
| Larry Todd Edwards | ORKA | Common Stock | Award | 100,000 | 100,000 | 24 Aug 2026 | Direct | |||
| Larry Todd Edwards | ORKA | Employee Stock Option (right to buy) | Award | 20,000 | 20,000 | 24 Aug 2026 | Direct | |||
| Joana Goncalves | ORKA | Common Stock | Sale | -17.6% | $782,882 | $111.84 | -7,000 | 32,718 | 17 Aug 2026 | Direct |
| Joana Goncalves | ORKA | Common Stock | Options Exercise | 21.4% | 7,000 | 39,718 | 17 Aug 2026 | Direct | ||
| Joana Goncalves | ORKA | Employee Warrant (right to buy) | Options Exercise | -2.03% | -3,500 | 168,492 | 17 Aug 2026 | Direct | ||
| Joana Goncalves | ORKA | Employee Stock Option (right to buy) | Options Exercise | -1.75% | -3,500 | 197,063 | 17 Aug 2026 | Direct | ||
| Quinlan Paul T. | ORKA | Common Stock | Sale | -62.6% | $5,641,409 | $108.49 | -52,000 | 31,034 | 14 Aug 2026 | Direct |
| Quinlan Paul T. | ORKA | Common Stock | Options Exercise | 167.6% | 52,000 | 83,034 | 14 Aug 2026 | Direct | ||
| Quinlan Paul T. | ORKA | Employee Stock Option (right to buy) | Options Exercise | -25.8% | -42,000 | 120,500 | 14 Aug 2026 | Direct | ||
| Quinlan Paul T. | ORKA | Employee Warrant (right to buy) | Options Exercise | -10% | -10,000 | 89,996 | 14 Aug 2026 | Direct | ||
| Arjun Agarwal | ORKA | Common Stock | Sale | -39.5% | $1,066,572 | $106.66 | -10,000 | 15,312 | 13 Aug 2026 | Direct |
| Arjun Agarwal | ORKA | Common Stock | Options Exercise | 65.3% | 10,000 | 25,312 | 13 Aug 2026 | Direct | ||
| Arjun Agarwal | ORKA | Employee Stock Option (right to buy) | Options Exercise | -14.3% | -10,000 | 59,792 | 13 Aug 2026 | Direct | ||
| Joana Goncalves | ORKA | Common Stock | Sale | -17.6% | $603,938 | $86.28 | -7,000 | 32,718 | 15 Jul 2026 | Direct |
| Joana Goncalves | ORKA | Common Stock | Options Exercise | 21.4% | 7,000 | 39,718 | 15 Jul 2026 | Direct | ||
| Joana Goncalves | ORKA | Employee Warrant (right to buy) | Options Exercise | -1.99% | -3,500 | 171,992 | 15 Jul 2026 | Direct | ||
| Joana Goncalves | ORKA | Employee Stock Option (right to buy) | Options Exercise | -1.72% | -3,500 | 200,563 | 15 Jul 2026 | Direct | ||
| Arjun Agarwal | ORKA | Common Stock | Sale | -39.5% | $846,180 | $84.63 | -9,999 | 15,312 | 13 Jul 2026 | Direct |
| Arjun Agarwal | ORKA | Common Stock | Options Exercise | 65.3% | 9,999 | 25,311 | 13 Jul 2026 | Direct | ||
| Arjun Agarwal | ORKA | Employee Stock Option (right to buy) | Options Exercise | -14% | -9,999 | 61,250 | 13 Jul 2026 | Direct | ||
| Fairmount Funds Management LLC | ORKA | Common Stock | Sale | -75.8% | $300,014,406 | $84.43 | -3,553,410 | 1,131,954 | 01 Jul 2026 | By Fairmount Healthcare Fund II L.P. |
| Fairmount Funds Management LLC | ORKA | Common Stock | Sale | -75.8% | $300,014,406 | $84.43 | -3,553,410 | 1,131,954 | 01 Jul 2026 | By Fairmount Healthcare Fund II L.P. |
| Fairmount Funds Management LLC | ORKA | Common Stock | Sale | -75.8% | $300,014,406 | $84.43 | -3,553,410 | 1,131,954 | 01 Jul 2026 | By Fairmount Healthcare Fund II L.P. |
| Fairmount Funds Management LLC | ORKA | Common Stock | Sale | -75.8% | $300,014,406 | $84.43 | -3,553,410 | 1,131,954 | 01 Jul 2026 | By Fairmount Healthcare Fund II L.P. |
| Fairmount Funds Management LLC | ORKA | Common Stock | Sale | -75.8% | $300,014,406 | $84.43 | -3,553,410 | 1,131,954 | 01 Jul 2026 | By Fairmount Healthcare Fund II L.P. |
| Fairmount Funds Management LLC | ORKA | Common Stock | Conversion of derivative security | 313.9% | 3,553,410 | 4,685,364 | 01 Jul 2026 | By Fairmount Healthcare Fund II L.P. | ||
| Fairmount Funds Management LLC | ORKA | Common Stock | Conversion of derivative security | 313.9% | 3,553,410 | 4,685,364 | 01 Jul 2026 | By Fairmount Healthcare Fund II L.P. | ||
| Fairmount Funds Management LLC | ORKA | Common Stock | Conversion of derivative security | 313.9% | 3,553,410 | 4,685,364 | 01 Jul 2026 | By Fairmount Healthcare Fund II L.P. | ||
| Fairmount Funds Management LLC | ORKA | Common Stock | Conversion of derivative security | 313.9% | 3,553,410 | 4,685,364 | 01 Jul 2026 | By Fairmount Healthcare Fund II L.P. | ||
| Fairmount Funds Management LLC | ORKA | Common Stock | Conversion of derivative security | 313.9% | 3,553,410 | 4,685,364 | 01 Jul 2026 | By Fairmount Healthcare Fund II L.P. | ||
| Fairmount Funds Management LLC | ORKA | Series B Preferred Stock | Conversion of derivative security | -31.1% | -42,641 | 94,497 | 01 Jul 2026 | By Fairmount Healthcare Fund II L.P. | ||
| Fairmount Funds Management LLC | ORKA | Series B Preferred Stock | Conversion of derivative security | -31.1% | -42,641 | 94,497 | 01 Jul 2026 | By Fairmount Healthcare Fund II L.P. | ||
| Fairmount Funds Management LLC | ORKA | Series B Preferred Stock | Conversion of derivative security | -31.1% | -42,641 | 94,497 | 01 Jul 2026 | By Fairmount Healthcare Fund II L.P. | ||
| Fairmount Funds Management LLC | ORKA | Series B Preferred Stock | Conversion of derivative security | -31.1% | -42,641 | 94,497 | 01 Jul 2026 | By Fairmount Healthcare Fund II L.P. | ||
| Fairmount Funds Management LLC | ORKA | Series B Preferred Stock | Conversion of derivative security | -31.1% | -42,641 | 94,497 | 01 Jul 2026 | By Fairmount Healthcare Fund II L.P. | ||
| Laura Lee Sandler | ORKA | Common Stock | Sale | -2.07% | $472,079 | $94.42 | -5,000 | 236,384 | 01 Jul 2026 | Direct |
| Laura Lee Sandler | ORKA | Common Stock | Options Exercise | 2.12% | 5,000 | 241,384 | 01 Jul 2026 | Direct | ||
| Laura Lee Sandler | ORKA | Employee Warrant (right to buy) | Options Exercise | -5.88% | -5,000 | 79,996 | 01 Jul 2026 | Direct | ||
| Arjun Agarwal | ORKA | Common Stock | Sale | -9.39% | $128,468 | $80.95 | -1,587 | 15,312 | 22 Jun 2026 | Direct |
| Arjun Agarwal | ORKA | Common Stock | Sale | -2.28% | $27,528 | $69.69 | -395 | 16,899 | 15 Jun 2026 | Direct |
| Joana Goncalves | ORKA | Common Stock | Sale | -19.5% | $550,607 | $69.28 | -7,947 | 32,718 | 15 Jun 2026 | Direct |
| Joana Goncalves | ORKA | Common Stock | Options Exercise | 20.8% | 7,000 | 40,665 | 15 Jun 2026 | Direct | ||
| Joana Goncalves | ORKA | Employee Warrant (right to buy) | Options Exercise | -1.96% | -3,500 | 175,492 | 15 Jun 2026 | Direct | ||
| Joana Goncalves | ORKA | Employee Stock Option (right to buy) | Options Exercise | -1.69% | -3,500 | 204,063 | 15 Jun 2026 | Direct |
* marks a reported price that did not pass the local price check.